114 related articles for article (PubMed ID: 3123071)
1. Functional differentiation of human lymphokine-activated killing (LAK) is distinct from expansion and involves dissimilar interleukin 2 receptors.
Owen-Schaub LB; Loudon WG; Yagita M; Grimm EA
Cell Immunol; 1988 Jan; 111(1):235-46. PubMed ID: 3123071
[TBL] [Abstract][Full Text] [Related]
2. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.
Kasid A; Bell GI; Director EP
J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414
[TBL] [Abstract][Full Text] [Related]
3. Functional studies on the precursors of human lymphokine-activated killer cells.
Gray JD; Shau HY; Golub SH
Cell Immunol; 1985 Dec; 96(2):338-50. PubMed ID: 3939293
[TBL] [Abstract][Full Text] [Related]
4. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
[TBL] [Abstract][Full Text] [Related]
5. The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities.
Siegel JP; Sharon M; Smith PL; Leonard WJ
Science; 1987 Oct; 238(4823):75-8. PubMed ID: 3116668
[TBL] [Abstract][Full Text] [Related]
6. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
Grimm EA; Mazumder A; Zhang HZ; Rosenberg SA
J Exp Med; 1982 Jun; 155(6):1823-41. PubMed ID: 6176669
[TBL] [Abstract][Full Text] [Related]
7. Novel interleukin 2 (IL-2) receptor appears to mediate IL-2-induced activation of natural killer cells.
Kehrl JH; Dukovich M; Whalen G; Katz P; Fauci AS; Greene WC
J Clin Invest; 1988 Jan; 81(1):200-5. PubMed ID: 2826541
[TBL] [Abstract][Full Text] [Related]
8. Direct activation of human resting T cells by IL 2: the role of an IL 2 receptor distinct from the Tac protein.
Bich-Thuy LT; Dukovich M; Peffer NJ; Fauci AS; Kehrl JH; Greene WC
J Immunol; 1987 Sep; 139(5):1550-6. PubMed ID: 3040856
[TBL] [Abstract][Full Text] [Related]
9. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
Owen-Schaub LB; Gutterman JU; Grimm EA
Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
[TBL] [Abstract][Full Text] [Related]
10. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
Peace DJ; Kern DE; Schultz KR; Greenberg PD; Cheever MA
J Immunol; 1988 May; 140(10):3679-85. PubMed ID: 2896213
[TBL] [Abstract][Full Text] [Related]
11. IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes.
Kawakami Y; Custer MC; Rosenberg SA; Lotze MT
J Immunol; 1989 May; 142(10):3452-61. PubMed ID: 2654291
[TBL] [Abstract][Full Text] [Related]
12. The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells.
Tsudo M; Goldman CK; Bongiovanni KF; Chan WC; Winton EF; Yagita M; Grimm EA; Waldmann TA
Proc Natl Acad Sci U S A; 1987 Aug; 84(15):5394-8. PubMed ID: 3110786
[TBL] [Abstract][Full Text] [Related]
13. Functional interactions of IL2 and TNF in the differentiation of LGL into LAK effectors.
Blay JY; Bertoglio J; Fradelizi D; Chouaib S
Int J Cancer; 1989 Oct; 44(4):598-604. PubMed ID: 2793231
[TBL] [Abstract][Full Text] [Related]
14. Lymphocytes expressing type 3 complement receptors proliferate in response to interleukin 2 and are the precursors of lymphokine-activated killer cells.
Gray JD; Horwitz DA
J Clin Invest; 1988 Apr; 81(4):1247-54. PubMed ID: 2965164
[TBL] [Abstract][Full Text] [Related]
15. Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.
Grimm EA; Robb RJ; Roth JA; Neckers LM; Lachman LB; Wilson DJ; Rosenberg SA
J Exp Med; 1983 Oct; 158(4):1356-61. PubMed ID: 6413638
[TBL] [Abstract][Full Text] [Related]
16. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.
Weil-Hillman G; Fisch P; Prieve AF; Sosman JA; Hank JA; Sondel PM
Cancer Res; 1989 Jul; 49(13):3680-8. PubMed ID: 2471587
[TBL] [Abstract][Full Text] [Related]
17. Generation of lymphokine-activated killer cells: synergy between tumor necrosis factor and interleukin 2.
Chouaib S; Bertoglio J; Blay JY; Marchiol-Fournigault C; Fradelizi D
Proc Natl Acad Sci U S A; 1988 Sep; 85(18):6875-9. PubMed ID: 3045826
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 2 (IL 2) up-regulates its own receptor on a subset of human unprimed peripheral blood lymphocytes and triggers their proliferation.
Harel-Bellan A; Bertoglio J; Quillet A; Marchiol C; Wakasugi H; Mishall Z; Fradelizi D
J Immunol; 1986 Apr; 136(7):2463-9. PubMed ID: 3005412
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
20. Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors.
Rayner AA; Grimm EA; Lotze MT; Wilson DJ; Rosenberg SA
J Natl Cancer Inst; 1985 Jul; 75(1):67-75. PubMed ID: 2989604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
